FDA Gives a Nod to Pulmonary Hypertension Drug

The U.S. Food and Drug Administration approved Bayer AG's drug to treat two types of pulmonary hypertension. The drug, Adempas, also known as riociguat, is designed to treat thromboembolic pulmonary hypertension, a rare disease typically caused by blood clots that restrict the flow of blood from the heart to the lungs. Read the full story